The efficacy and response of switching from either donepezil or galantamine to rivastigmine transdermal patch in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial
Not Applicable
- Conditions
- Alzheimer disease
- Registration Number
- JPRN-UMIN000010556
- Lead Sponsor
- Department of Neuropsychiatry, Keio University School of Medicine,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Not provided
Exclusion Criteria
either previous history or now taking other choline inhibitors (rivastigmine) and memantine, taking antipsychotic or antidepressant medication ,there was a previous history of mental illness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings , the patient has pacemaker, other findings in terms with the aims of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method multi-modal neuroimaging analysis 1 Structural neuroimaging analysis Brain MRI: voxel-based morphometry (VBM) diffusion tensor imaging (DTI) 2 Functional neuroimaging analysis single photon emission computed tomography (SPECT) near-infrared spectroscopy (NIRS)
- Secondary Outcome Measures
Name Time Method 1 Cognitive assessment Mini-Mental State Examination (MMSE) Clock drawing test The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog) Frontal assessment battery (FAB) 2 Behavior assessment Clinical assessment for spontaneity (CAS) Neuropsychiatry Inventory Questionnaire (NPI-Q) Quality of life-Alzheimer Disease (QOL-AD) Scale